ABL1 and neoplasm: We therefore conducted a comparative investigation of targeting DDR1 in combination with EGFR inhibitor (lapatinib), utilizing an additional tumor model of GBM and including the brain penetrable DDR1/BCR-ABL inhibitor nilotinib to evaluate its combinatorial efficacy.